• Injection Depth: Match to target tissue; mid-dermal for moderate wrinkles, subcutaneous for volume restoration and hand rejuvenation.
• Techniques: Use linear threading, fanning, serial puncture, or cross-hatching based on patient anatomy and tissue quality.
• Anesthesia: Gel contains 3 mg/mL lidocaine; supplementary topical anesthesia is optional.
• Safety & Administration: Maintain strict aseptic technique. Avoid intravascular injection and overcorrection, and perform careful tissue assessment for dorsum hand rejuvenation.
• Post-Treatment Guidance: Advise patients to avoid sun exposure, intense heat, alcohol, and strenuous activity until redness, swelling, or tenderness subsides.
• Adverse Events & Warnings: Monitor for potential vascular occlusion, skin necrosis, visual disturbances, transient bruising, and localized edema.

• Can treat moderate-to-deep wrinkle correction, including nasolabial folds, marionette lines, and perioral rhytids, depending on local labeling and clinical assessment.
• Indicated for facial volume restoration in areas such as the cheeks, chin, and selected lip applications, using mid-to-deep dermal or subcutaneous injection techniques as appropriate.
• Can deliver hand rejuvenation, particularly to correct volume loss on the dorsum of the hand.
• Prescribed for administration by licensed aesthetic medicine professionals only and is not intended for self-administration.

Product Specifications

• Active ingredient: Cross-linked hyaluronic acid 20 mg/g; mannitol 9 mg/mL; lidocaine 3 mg/mL.
• Format: Injectable gel supplied in 2 × 1 mL prefilled syringes with 30G ½ needles.
• Manufacturer: Laboratoires VIVACY, France.
• Drug class: Injectable cross-linked hyaluronic acid dermal filler with mannitol and lidocaine.
• Technology: IPN-Like Technology™; BI-FLEX® patented syringe system (formerly Bi-SOFT®).
• Regulatory status: CE-marked for EU use; US FDA status should be verified by jurisdiction before procurement.

Contraindications

• Do not administer to patients with known hypersensitivity to hyaluronic acid, lidocaine, amide-type anesthetics, mannitol, or any excipient in the formulation.
• Do not inject into areas with active skin infection, inflammation, open wounds, or untreated lesions at the intended treatment site.
• Avoid use during pregnancy or breastfeeding as a precaution, due to limited safety data in these populations.

• Administer by intradermal, deep dermal, or subcutaneous injection only; use mid-dermal depth for wrinkle correction and subcutaneous placement for volume restoration and hand rejuvenation.
• Topical anesthesia is optional, as lidocaine 3 mg/mL is already co-formulated in the gel.
• Allow the syringe to reach room temperature before administration to support smoother gel flow and controlled injection.
• The product is intended for single use only; discard any unused gel, syringe, and needle after the procedure. Do not re-sterilize or reuse after opening.
• Screen for hypersensitivity to hyaluronic acid and amide-type anesthetics before treatment and refer to the full IFU.

Legal & Regulatory Status

STYLAGE® M BI-FLEX® with Lidocaine is a CE-marked medical device manufactured by Laboratoires VIVACY (France). Its regulatory status in other jurisdictions, including the United States, should be verified before procurement. Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact the Med Supply Solutions support team for sourcing information and documentation support.

1. Micheels P, Sarazin D, Tran C, Salomon D. Effect of Different Crosslinking Technologies on Hyaluronic Acid Behavior: A Visual and Microscopic Study of Seven Hyaluronic Acid Gels. J Drugs Dermatol. 2016;15(5):600-606.
2. Mole B, Gozlan L. Benefits of adding lidocaine to a hyaluronic gel – Stylage® M. J Cosmet Laser Ther. 2011;13(5):249-254. doi:10.3109/14764172.2011.613478

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.